News and Events

The HIV care landscape is constantly evolving, with breakthroughs in the methods, strategies and treatments to control and prevent transmission. This section aims to provide timely news updates and clinically relevant information about HIV disease management to clinicians who are actively involved in HIV care.

Upcoming events such as conferences, online seminars and continuing education programs will be listed here on a regular basis.

17th June 2019

Patient-reported outcomes have adjusted with the needs of PLHIV

This is the first in a three-part series on patient reported outcomes (PROs) and how they can be incorporated into the clinical management of people living with HIV (PLHIV). The series includes expert insights from Dr Hal Martin, Director of Clinical Research at Gilead Sciences, San Francisco, California, and includes a link to the HIV Symptom Index – the most commonly used instrument to measure PROs in PLHIV.

7th June 2019

DHHS and EACS update HIV treatment guidelines

As the treatment and management of people living with HIV (PLHIV) continues to evolve, the most updated versions of guidelines should be consulted. Guidelines issued by US Department of Health and Human Services (DHHS) and the European AIDS Clinical Society (EACS) are commonly used by HIV clinicians and are routinely updated to reflect the current literature.

5th June 2019

New US and EU guidelines recommend Gilead’s BIKTARVY® (bictegravir / emtricitabine / tenofovir alafenamide)

In October 2018, the US Department of Health and Human Services (DHHS) and the European AIDS Clinical Society (EACS) released new guidelines for the management of people living with HIV (PLHIV). Both guidelines incorporated Gilead’s once-daily, single tablet regimen (STR), BIKTARVY®, which comprises an integrase strand transfer inhibitor [INSTI; bictegravir (BIC)] combined with two nucleoside reverse transcriptase inhibitors [NRTIs; emtricitabine (FTC) and tenofovir alafenamide (TAF)].1-3

29th May 2019

Study reveals improvements in renal function following medication switch

Results from a real-world study show reassuring improvements in renal function after switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)*1 from E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF) and provide additional clinical evidence that, in comparison to tenofovir disoproxil fumarate (TDF), TAF is associated with significantly less tenofovir (TFV) plasma exposure2,3 and a reduction in off-target effects.4 The findings also concur with guidelines issued by the US Department of Health and Human Services (DHHS).5

15th May 2019

Grant applications now open

In the third installment of NoCo, this program will fund approximately six to eight projects with a total commitment of US $3M focused on investigating strategies to link patients living with HCV and HIV co-infection to HCV treatment.

1st November 2018

‘HIV is’ going The Full 360

Significant advances in HIV treatment and management mean that many people living with HIV (PLHIV) can now expect to live as long as the general population.1

30th October 2018

Is HIV sorted?

Advances in treatment and early diagnosis mean that today people living with HIV (PLHIV) can expect to live as long as the general population.1 However, new results from two large surveys suggest that there is a major disconnect between what the science tells us, community perceptions towards HIV, and the life expectations of PLHIV.

29th October 2018

The Full 360 launched at AIDS 2018

July 2018: at AIDS 2018, significant attention was devoted to ‘The Full 360.’  With a global prevalence approaching 37 million1 and an average age that continues to grow,2 more and more focus has been given to the lifelong good health of people living with HIV (PLHIV).